Topotecan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Topotecan: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Topotecan is a topoisomerase I inhibitor originally approved for platinum-refractory ovarian cancer, small cell lung cancer, and cervical cancer. The TxGNN model predicts it may be effective for Female Breast Carcinoma, with 5 clinical trials and 20 publications currently identified in support of this direction — though most of the trial-level evidence involves combination regimens or adjacent tumor types rather than confirmatory breast cancer monotherapy studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this regulatory dataset; per established pharmacology, Topotecan (Hycamtin) is originally indicated for platinum-refractory ovarian cancer, small cell lung cancer, and cervical cancer |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
The original_moa field in this dataset is marked as a data gap, and detailed DrugBank mechanism-of-action data has not yet been retrieved. Based on the evidence collected for this prediction, Topotecan’s pharmacology is nonetheless well characterized: it is a semisynthetic camptothecin derivative that inhibits topoisomerase I by stabilizing the topo I–DNA cleavable complex, generating DNA double-strand breaks during replication that trigger apoptosis in rapidly dividing cells (PMID 10472342). This mechanism underlies broad-spectrum activity across solid tumors, including in vivo activity against breast carcinoma xenografts.
Breast carcinoma shares the high-proliferation, chemosensitive biology of Topotecan’s approved indications, which is why the drug has been repeatedly tested in advanced/metastatic breast cancer since the 1990s — including a CALGB Phase 2 monotherapy trial (PMID 10362325), infusional-dosing studies (PMID 9413954), and combination regimens with paclitaxel (PMID 9626200) or as part of the TIME regimen (Topotecan/Ifosfamide/Etoposide, NCT00006032) prior to autologous stem cell rescue.
Despite this history, the mechanistic case has not translated into guideline adoption: across three decades of trials, Topotecan showed moderate but not superior activity relative to anthracycline/taxane-based standards, with dose-limiting myelosuppression consistently reported. More recent mechanistic work suggests renewed interest specifically in triple-negative breast cancer (TNBC), where TFDP1 has been proposed as a Topotecan-relevant therapeutic target through suppression of cellular senescence (PMID 40300683), and where BCRP/P-glycoprotein-mediated resistance pathways have been characterized in detail (PMID 10930538, PMID 25236865) — pointing to potential combination strategies (e.g., with BCRP inhibitors) that could revive this indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02282020 | Phase 3 | Completed | 266 | Olaparib vs. physician’s-choice chemotherapy in gBRCA1/2-mutated platinum-sensitive relapsed ovarian cancer; Topotecan’s specific role in this regimen could not be confirmed from the trial title alone and requires further verification |
| NCT04739800 | Phase 2 | Active, not recruiting | 120 | Durvalumab + olaparib + cediranib vs. standard chemotherapy in platinum-resistant recurrent ovarian/peritoneal/fallopian tube cancer; whether Topotecan serves as the chemotherapy backbone is unconfirmed |
| NCT00006032 | Phase 2 | Terminated | N/A | TIME regimen (Topotecan + Ifosfamide/Mesna + Etoposide) followed by autologous stem cell rescue, designed specifically for metastatic breast cancer; trial was terminated |
| NCT04279509 | N/A (organoid screen) | Unknown | 35 | Patient-derived organoid drug-screening study (SCORE) for refractory solid tumors; provides in vitro drug-sensitivity data only, not a therapeutic intervention trial |
| NCT02419495 | Phase 1 | Terminated | 221 | Selinexor combined with multiple standard chemotherapy/immunotherapy regimens in advanced malignancies; Topotecan’s specific relevance to the breast cancer arm is unclear |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10362325 | 1999 | RCT/Phase 2 | American Journal of Clinical Oncology | CALGB Phase 2 trial of Topotecan monotherapy in 53 previously treated advanced breast cancer patients (47 eligible, 40 evaluable) |
| 9413954 | 1997 | Phase 2 | British Journal of Cancer | Two open Phase 2 studies of continuous infusional Topotecan in chemo-naive advanced breast cancer and NSCLC; no evidence of increased efficacy over standard dosing |
| 11455218 | 2001 | Cohort/Pilot | Onkologie | Pilot study of Topotecan as primary chemotherapy for symptomatic brain metastases in metastatic breast cancer |
| 39013199 | 2024 | Review/Expert Consensus | Revista Colombiana de Obstetricia y Ginecología | Expert consensus on profiling and management of advanced/metastatic epithelial ovarian cancer; contextual reference, not breast-cancer specific |
| 10472342 | 1999 | Preclinical | Anticancer Research | Human breast, colon, and lung carcinoma xenografts tested against doxorubicin, cisplatin, irinotecan, and Topotecan; Topotecan showed measurable in vivo activity against breast cancer cell lines |
| 27444351 | 2016 | Preclinical/Mechanistic | Phytomedicine | MHP-1 (a Cordyceps-derived compound) restores Topotecan sensitivity and inhibits metastasis via EMT/TGF-β regulation in breast cancer cells |
| 40300683 | 2025 | Preclinical/Mechanistic | International Journal of Biological Macromolecules | TFDP1 identified as a driver of triple-negative breast cancer via senescence suppression and proposed as a therapeutic target for Topotecan |
| 9626200 | 1998 | Phase 2 | Journal of Clinical Oncology | Phase 2 trial of paclitaxel + Topotecan with G-CSF support in pretreated Stage IV breast cancer; pharmacokinetics correlated with toxicity |
| 21514634 | 2011 | Phase 2 | Gynecologic Oncology | Phase 2 trial of lapatinib + Topotecan (LapTop) in platinum-refractory/resistant ovarian and peritoneal carcinoma, targeting BCRP/P-gp-mediated Topotecan resistance |
| 31408695 | 2019 | Preclinical/Mechanistic | Pharmacological Research | Daidzein enhances Topotecan’s anticancer effect and reverses BCRP-mediated drug resistance in breast cancer models |
EU Market Information
Topotecan currently has no recorded marketing authorization in this EU regulatory dataset (market status: Not marketed, 0 authorizations on file). No license-level detail (product name, dosage form, or approved indication text) is available for extraction.
Cytotoxicity
Topotecan is a conventional cytotoxic chemotherapy agent (camptothecin-class topoisomerase I inhibitor), meeting the antineoplastic classification criteria.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (topoisomerase I inhibitor, camptothecin derivative) |
| Myelosuppression Risk | High — directly documented in the evidence base: in a Phase 2 trial of Topotecan in cisplatin-refractory germ cell tumors, myelosuppression was the dose-limiting toxicity, with median nadir leukocyte count 1.75 ×10⁹/L, neutrophil count 1.55 ×10⁹/L, hemoglobin 8.75 g/dL, and platelet count 20,500/mm³ (PMID 8617580) |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Complete blood count with differential (neutrophils, platelets), given documented severe myelosuppression; renal function (Topotecan undergoes renal clearance) |
| Handling Protection | Must follow standard cytotoxic/hazardous drug handling regulations |
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug interaction data are not available in this evidence pack — notably, the absence of TFDA label warnings/contraindications is flagged as a blocking data gap (DG001), which prevents this candidate from entering the S1 safety pre-screening stage.
Conclusion and Next Steps
Decision: Research Question
Rationale: Mechanistic plausibility and a long track record of Phase 2 exploration in breast cancer exist, but no trial has established Topotecan as competitive with anthracycline/taxane-based standards, and the most directly relevant breast-cancer-specific trial (TIME regimen, NCT00006032) was terminated. Combined with a blocking gap in safety labeling data (DG001), the evidence supports further targeted research rather than a Go/Hold decision at this time.
To proceed, the following is needed:
- TFDA/EMA-approved label warnings and contraindications (DG001, blocking — required before S1 safety pre-screening)
- Structured DrugBank mechanism-of-action data (DG002)
- Confirmation of Topotecan’s actual regimen role in NCT02282020 and NCT04739800, both of which appear ovarian-cancer-focused based on trial titles
- Updated clinical evidence on Topotecan combination strategies (e.g., with BCRP/P-gp inhibitors) specifically in HER2-negative or triple-negative breast cancer populations, building on the TFDP1 mechanistic rationale (PMID 40300683)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.